Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Hadaschik

Showing results (1-10 of 268) with videos related to

Pageof 27
Sort By:
European Urology|August 25, 2016
Re: <sup>225</sup>Ac-PSMA-617 for PSMA-Targeting Alpha-radiation Therapy of Patients with Metastatic Castration-resistant Prostate CancerBoris Hadaschik
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|September 3, 2021
[Radiation therapy in high-risk and very high-risk localized or locally advanced prostate cancer : Prostate-only versus prostate plus whole-pelvic?]Martin Stuschke, Boris Hadaschik
European Urology|May 7, 2020
Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre StudyBoris Hadaschik, Ken Herrmann
European Urology|July 27, 2021
Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate CancerBoris Hadaschik, Ken Herrmann
Der Urologe. Ausg. A|April 12, 2022
[Imaging update for urologists : Modern diagnostics in hospitals and medical practices]Boris Hadaschik, Christian Stief
European Urology|July 31, 2025
Re: Salvage Metastasis-directed Therapy Versus Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases (PEACE V-STORM): A Phase 2, Open-label, Randomised Controlled TrialChristian Thomas, Boris Hadaschik
European Urology|May 16, 2021
Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell CarcinomaViktor Grünwald, Boris Hadaschik
Urologie (Heidelberg, Germany)|March 11, 2025
[Update on metastatic prostate cancer : Choices bring challenges]Christian Thomas, Boris Hadaschik
Der Urologe. Ausg. A|February 12, 2021
[Treatment of nonmetastatic CRPC : Androgen receptor inhibition as new treatment standard in nonmetastatic castration-resistant prostate cancer with high risk of metastasis]Boris Hadaschik, Eva Hellmis
European Urology|May 20, 2017
Re: Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT Before Salvage Lymph Node Dissection for Recurrent Prostate CancerBoris Hadaschik, Ken Herrmann
Pageof 27

Showing results (1-10 of 268) with videos related to

Sort By:
Pageof 27
European Urology|August 25, 2016
Re: <sup>225</sup>Ac-PSMA-617 for PSMA-Targeting Alpha-radiation Therapy of Patients with Metastatic Castration-resistant Prostate CancerBoris Hadaschik
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|September 3, 2021
[Radiation therapy in high-risk and very high-risk localized or locally advanced prostate cancer : Prostate-only versus prostate plus whole-pelvic?]Martin Stuschke, Boris Hadaschik
European Urology|May 7, 2020
Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre StudyBoris Hadaschik, Ken Herrmann
European Urology|July 27, 2021
Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate CancerBoris Hadaschik, Ken Herrmann
Der Urologe. Ausg. A|April 12, 2022
[Imaging update for urologists : Modern diagnostics in hospitals and medical practices]Boris Hadaschik, Christian Stief
European Urology|July 31, 2025
Re: Salvage Metastasis-directed Therapy Versus Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases (PEACE V-STORM): A Phase 2, Open-label, Randomised Controlled TrialChristian Thomas, Boris Hadaschik
European Urology|May 16, 2021
Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell CarcinomaViktor Grünwald, Boris Hadaschik
Urologie (Heidelberg, Germany)|March 11, 2025
[Update on metastatic prostate cancer : Choices bring challenges]Christian Thomas, Boris Hadaschik
Der Urologe. Ausg. A|February 12, 2021
[Treatment of nonmetastatic CRPC : Androgen receptor inhibition as new treatment standard in nonmetastatic castration-resistant prostate cancer with high risk of metastasis]Boris Hadaschik, Eva Hellmis
European Urology|May 20, 2017
Re: Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT Before Salvage Lymph Node Dissection for Recurrent Prostate CancerBoris Hadaschik, Ken Herrmann
Pageof 27